← All Protagonist Therapeutics, INC filings

Protagonist Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
PTGX
Protagonist Therapeutics, INC
DEF: Protagonist Therapeutics Sets June 17 Annual Meeting
Protagonist Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing director elections, executive compensation, and equity plan proposals.
NASDAQ
PTGX
Protagonist Therapeutics, INC
DEFA14A: Protagonist Therapeutics Sets Date for 2025 Annual Meeting, Outlines Voting Matters
Protagonist Therapeutics has scheduled its 2025 Annual Meeting of Stockholders for June 20, 2025, outlining key voting items for shareholders.
NASDAQ
PTGX
Protagonist Therapeutics, INC
DEF: Protagonist Therapeutics Sets Date for 2025 Annual Stockholders Meeting
Protagonist Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 20, 2025, covering director elections, executive compensation, and auditor ratification.
NASDAQ
PTGX
Protagonist Therapeutics, INC
DEFA14A: Protagonist Therapeutics Sets Date for 2024 Annual Meeting, Proposes Share Increase
Protagonist Therapeutics will hold its annual meeting on June 20, 2024, with proposals including the election of directors, executive compensation, ratification of Ernst & Young LLP as auditor, and an increase in authorized common stock.
NASDAQ
PTGX
Protagonist Therapeutics, INC
DEF 14A: Protagonist Therapeutics Seeks Stockholder Approval for Increased Authorized Shares and Director Elections at Upcoming Annual Meeting
Protagonist Therapeutics is holding its annual meeting on June 20, 2024, to vote on director elections, executive compensation, auditor ratification, and an increase in authorized common stock.